HC Wainwright Brokers Raise Earnings Estimates for NovoCure

NovoCure Limited (NASDAQ:NVCR) – Research analysts at HC Wainwright lifted their Q4 2025 EPS estimates for shares of NovoCure in a report released on Tuesday, January 13th. HC Wainwright analyst E. Bodnar now anticipates that the medical equipment provider will post earnings of ($0.30) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($1.08) EPS, FY2028 earnings at ($0.34) EPS and FY2029 earnings at $1.07 EPS.

Several other equities research analysts also recently commented on NVCR. Evercore ISI set a $20.00 target price on NovoCure in a report on Monday, January 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a report on Wednesday, October 8th. Wedbush restated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a report on Thursday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of NovoCure from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Monday, October 27th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, NovoCure currently has an average rating of “Hold” and a consensus price target of $25.50.

NovoCure Price Performance

Shares of NASDAQ:NVCR opened at $13.64 on Thursday. The company has a market capitalization of $1.53 billion, a PE ratio of -8.47 and a beta of 0.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. The stock has a fifty day moving average of $12.77 and a 200-day moving average of $13.19. NovoCure has a one year low of $10.70 and a one year high of $27.47.

NovoCure (NASDAQ:NVCR) last issued its earnings results on Thursday, October 30th. The medical equipment provider reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. The firm had revenue of $167.20 million during the quarter, compared to analysts’ expectations of $158.81 million. NovoCure had a negative net margin of 27.66% and a negative return on equity of 50.29%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.28) earnings per share.

Institutional Trading of NovoCure

Several large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its holdings in shares of NovoCure by 56.7% during the 1st quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider’s stock valued at $512,000 after purchasing an additional 10,394 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in NovoCure by 3.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after buying an additional 2,502 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in NovoCure by 5.5% during the first quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock valued at $17,707,000 after buying an additional 52,180 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of NovoCure in the first quarter worth about $87,000. Finally, Strs Ohio bought a new stake in shares of NovoCure during the 1st quarter worth about $759,000. 84.61% of the stock is owned by institutional investors.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating on NovoCure, supporting demand from growth-oriented investors who focus on long‑term upside potential. Piper Sandler Remains a Buy on NovoCure (NVCR)
• Neutral Sentiment: Wells Fargo moved to a Hold on NVCR, which is neither bullish nor bearish but reduces conviction among buyers waiting for stronger fundamental signals. NovoCure (NVCR) Gets a Hold from Wells Fargo
• Neutral Sentiment: Wedbush reaffirmed a neutral rating with an $18 price target (implying meaningful upside from current levels), a signal that some brokerages see potential but want better near‑term evidence of margin or revenue acceleration. Benzinga
• Neutral Sentiment: Market consensus across analysts remains a “Hold,” reflecting mixed views and likely contributing to muted trading volume and hesitation among broader investor groups. NovoCure Given Consensus Rating of “Hold”
• Negative Sentiment: HC Wainwright cut multiple near‑term and multi‑year EPS forecasts (Q1–Q4 2026, FY2026–2028 and FY2029) and trimmed its price view — even while maintaining a Buy and a $39 target — signaling weaker expected profitability and introducing downside risk to sentiment. That cluster of estimate cuts is the most direct negative catalyst driving selling pressure. HC Wainwright Lowers NovoCure (NVCR) Price Target to $39.00

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.